Information Provided By:
Fly News Breaks for August 7, 2018
BIIB, IONS
Aug 7, 2018 | 07:57 EDT
Stifel transferred coverage of Ionis Pharmaceuticals (IONS) to analyst Paul Matteis, who set a Hold rating and $48 price target on the shares. The Biogen (BIIB) deal, while validating, limits some of the future upside for Ionis, Matteis tells investors. Also, despite his long-term bullishness on the TTR amyloidisis opportunity, he is below consensus for the first year of the launches for Tegsedi and Waylivra.
News For IONS;BIIB From the Last 2 Days
There are no results for your query IONS;BIIB